{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:20:19Z","timestamp":1792686019658,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1001\/jamaoncol.2018.4628","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T12:30:27Z","timestamp":1541075427000},"page":"195","source":"Crossref","is-referenced-by-count":287,"title":["Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1\u2013Low\/Negative Recurrent or Metastatic HNSCC"],"prefix":"10.1001","volume":"5","author":[{"given":"Lillian L.","family":"Siu","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Even","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Cancer, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Mes\u00eda","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology\u2013Badalona, University of Barcelona, IDIBELL, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Remenar","sequence":"additional","affiliation":[{"name":"Fej-nyak \u00c1llcsont, Rekonstrukci\u00f3s Plasztikai Seb\u00e9szeti \u00e9s Laser Seb\u00e9szeti Oszt\u00e1ly, Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaury","family":"Daste","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital Saint Andr\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Krauss","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisle","family":"Nabell","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal E.","family":"Ready","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bra\u00f1a","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Vall d\u2019Hebron University Hospital, Universitat Autonoma de Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Kotecki","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Canc\u00e9rologie Cervico-Faciale, Centre de Lutte Contre le Cancer\u2013Centre Oscar Lambret, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan P.","family":"Zandberg","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Henry-Joyce Cancer Clinic, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Mehanna","sequence":"additional","affiliation":[{"name":"Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Bonomi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Jarkowski","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, Maryland"},{"name":"Now with Bristol-Myers Squibb, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Melillo","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon M.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Wildsmith","sequence":"additional","affiliation":[{"name":"Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Fayette","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Cancer Center Centre L\u00e9on B\u00e9rard, University of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"coi180088r1","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/annonc\/mdf172","article-title":"End points for new agents in induction chemotherapy for locally advanced head and neck cancers.","volume":"13","author":"Monnerat","year":"2002","journal-title":"Ann Oncol"},{"key":"coi180088r2","doi-asserted-by":"publisher","first-page":"vii252","DOI":"10.1093\/annonc\/mdq453","article-title":"Optimal treatment for recurrent\/metastatic head and neck cancer.","volume":"21","author":"Vermorken","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"coi180088r3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4161\/15384047.2014.961881","article-title":"Gefitinib, methotrexate and methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.","volume":"16","author":"Kushwaha","year":"2015","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"coi180088r4","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2008.17.0530","article-title":"Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck","volume":"27","author":"Stewart","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi180088r5","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi180088r6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/jjco\/hym059","article-title":"Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).","volume":"37","author":"Zenda","year":"2007","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"coi180088r7","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3390\/cancers7040900","article-title":"Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches.","volume":"7","author":"Allen","year":"2015","journal-title":"Cancers (Basel)"},{"issue":"4","key":"coi180088r8","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/1078-0432.CCR-14-2481","article-title":"Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.","volume":"21","author":"Keck","year":"2015","journal-title":"Clin Cancer Res"},{"key":"coi180088r11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/annonc\/mdw376.01","article-title":"Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort","volume":"27","author":"Segal","year":"2016","journal-title":"Ann Oncol"},{"issue":"26","key":"coi180088r13","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"7528","key":"coi180088r14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"3","key":"coi180088r15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"coi180088r16","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/jco.2015.33.15_suppl.8033","article-title":"Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.","volume":"33","author":"Rebelatto","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi180088r19","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"coi180088r20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/CJI.0b013e3181c01fcb","article-title":"Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.","volume":"33","author":"Mangsbo","year":"2010","journal-title":"J Immunother"},{"issue":"4","key":"coi180088r21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"coi180088r22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma.","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"35","key":"coi180088r23","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.","volume":"23","author":"Ribas","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi180088r24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2217\/imt.13.9","article-title":"Tremelimumab: a review of development to date in solid tumors.","volume":"5","author":"Tarhini","year":"2013","journal-title":"Immunotherapy"},{"issue":"3","key":"coi180088r26","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-09-2033","article-title":"Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.","volume":"16","author":"Kirkwood","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"coi180088r27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"coi180088r29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/annonc\/mdx440.040","article-title":"Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC): phase 3 KEYNOTE-040 trial","volume":"28","author":"Cohen","year":"2017","journal-title":"Ann Oncol"},{"issue":"19","key":"coi180088r30","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"coi180088r31","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study.","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi180088r33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"issue":"1","key":"coi180088r34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"coi180088r35","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"32","key":"coi180088r36","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort.","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi180088r37","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"coi180088r9","year":"2017"},{"key":"coi180088r10","year":"2017"},{"key":"coi180088r12","author":"Zandberg","year":"2017"},{"key":"coi180088r17","author":"Segal","year":"2014"},{"key":"coi180088r18","author":"Wildsmith","year":"2018"},{"key":"coi180088r25","author":"Balar","year":"2018"},{"key":"coi180088r32","author":"Soulieres","year":"2018"},{"key":"coi180088r28","unstructured":"US Dept of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf. Published May 28, 2009. Accessed October 1, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/2\/195\/17295259\/jamaoncology_siu_2018_oi_180088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T10:32:45Z","timestamp":1572431565000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.4628"}},"subtitle":["The Phase 2 CONDOR Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.4628","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734352410.793553981","asserted-by":"object"}]},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}